Targeting HER2-positive breast cancer: advances and future directions
SM Swain, M Shastry, E Hamilton - Nature reviews Drug discovery, 2023 - nature.com
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …
Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with …
Importance It is estimated that up to 50% of patients with ERBB2 (HER2)-positive metastatic
breast cancer (MBC) will develop brain metastases (BMs), which is associated with poor …
breast cancer (MBC) will develop brain metastases (BMs), which is associated with poor …
[HTML][HTML] Leptomeningeal metastases: new opportunities in the modern era
JA Wilcox, MJ Li, AA Boire - Neurotherapeutics, 2022 - Elsevier
Leptomeningeal metastases arise from cancer cell entry into the subarachnoid space,
inflicting significant neurologic morbidity and mortality across a wide range of malignancies …
inflicting significant neurologic morbidity and mortality across a wide range of malignancies …
[HTML][HTML] 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)
F Cardoso, S Paluch-Shimon, E Schumacher-Wulf… - The breast, 2024 - Elsevier
This manuscript describes the Advanced Breast Cancer (ABC) international consensus
guidelines updated at the last two ABC international consensus conferences (ABC 6 in …
guidelines updated at the last two ABC international consensus conferences (ABC 6 in …
Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines
C Simmons, D Rayson, AA Joy… - Therapeutic …, 2022 - journals.sagepub.com
Background: Evidence to date supports continued human epidermal growth factor receptor 2
(HER2) suppression beyond progression on HER2-directed therapy for advanced HER2 …
(HER2) suppression beyond progression on HER2-directed therapy for advanced HER2 …
[HTML][HTML] Leptomeningeal metastasis from solid tumours: EANO–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
E Le Rhun, M Weller, M van den Bent, D Brandsma… - ESMO open, 2023 - Elsevier
These joint European Association of Neuro-Oncology (EANO)–European Society for
Medical Oncology (ESMO) recommendations for the diagnosis and treatment of …
Medical Oncology (ESMO) recommendations for the diagnosis and treatment of …
[HTML][HTML] Pharmacotherapy for leptomeningeal disease in breast cancer
Clinical data supporting the best therapeutic approach in leptomeningeal disease (LMD;
also known as leptomeningeal metastases or leptomeningeal carcinomatosis) are lacking …
also known as leptomeningeal metastases or leptomeningeal carcinomatosis) are lacking …
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases
Background Patients with HER2+ breast cancer (BC) frequently develop leptomeningeal
metastases (LM). While HER2-targeted therapies have demonstrated efficacy in the …
metastases (LM). While HER2-targeted therapies have demonstrated efficacy in the …
Neratinib and capecitabine for the treatment of leptomeningeal metastases from HER2-positive breast cancer: a series in the setting of a compassionate program
A Pellerino, R Soffietti, F Bruno, R Manna, E Muscolino… - Cancers, 2022 - mdpi.com
Simple Summary Leptomeningeal metastases represent an unmet need due to the lack of
effective therapy and poor survival. The tyrosine kinase inhibitor, neratinib, has …
effective therapy and poor survival. The tyrosine kinase inhibitor, neratinib, has …
Leveraging molecular and immune-based therapies in leptomeningeal metastases
JA Wilcox, AA Boire - CNS drugs, 2023 - Springer
Leptomeningeal metastases represent an aggressive stage of cancer with few durable
treatment options. Improved understanding of cancer biology, neoplastic reliance on …
treatment options. Improved understanding of cancer biology, neoplastic reliance on …